Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway.

@article{Fan2018MetforminST,
  title={Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway.},
  author={Hongjun Fan and Xiying Yu and Z. Zou and Wei Zheng and X. Deng and L. Guo and W. Jiang and Q. Zhan and S. Lu},
  journal={Carcinogenesis},
  year={2018}
}
  • Hongjun Fan, Xiying Yu, +6 authors S. Lu
  • Published 2018
  • Chemistry, Medicine
  • Carcinogenesis
  • Metformin is a widely used anti-diabetic drug for the management of type 2 diabetes mellitus. Recently, epidemiological studies demonstrate that metformin has anti-cancer effects on esophageal squamous cell carcinoma (ESCC) and other cancers. However, the effects and potential mechanisms of metformin on ESCC remain elusive. In this study, we employed N-nitroso-N-methylbenzylamine (NMBzA), a special carcinogen for esophagi, to develop a rat ESCC model, in which the carcinogenesis progression of… CONTINUE READING
    6 Citations

    References

    SHOWING 1-10 OF 43 REFERENCES
    Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
    • 79
    Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways
    • 31
    Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma
    • 14
    • PDF
    Metformin Inhibits Skin Tumor Promotion in Overweight and Obese Mice
    • 38
    • PDF
    Metformin targets c-MYC oncogene to prevent prostate cancer.
    • 94
    • PDF
    Metformin: An anti-diabetic drug to fight cancer.
    • 74
    [Natural compounds in chemoprevention of esophageal squamous cell tumors--experimental studies].
    • J. Szumiło
    • Medicine
    • Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
    • 2009
    • 4